Sweden's AI‑Driven Life Science Sector Gains Momentum

Swedish life‑science pioneer Mathias Uhlén highlights the rapid integration of artificial intelligence and data analytics into biological research. At SciLifeLab, a hub of roughly 3,000 scientists, Uhlén’s protein atlas provides a global reference for all human proteins and genes, forming the foundation for AI‑powered virtual cell models and accelerated drug discovery. His involvement in over 30 start‑ups, including a billion‑dollar company developing a cancer drug in Phase 3, reflects the commercial potential of data‑driven approaches, with additional trials for Alzheimer’s, gout and Parkinson’s therapies underway.

Parallel analysis shows a surge in demand for natural scientists with digital competence: a 228 % rise in required skills over the past decade and more than an 11,000 % increase in investment, driven largely by foundations and EU funds. Experts warn that insufficient long‑term state financing threatens the translation of research into marketable products. Proposed policy measures include a national coordination unit for data‑driven life science, streamlined migration procedures for international researchers, and enhanced capacity of regulatory agencies. With neighboring countries increasing funding, Sweden has a strategic window to cement its leadership in this AI‑enabled sector, securing export revenues and high‑skill jobs.